Search
Rucaparib
go.drugbank.com/drugs/DB12332ApprovedInvestigationalRucaparib is an anticancer drug and poly (ADP-ribose) polymerase (PARP) inhibitor. PARP is an enzyme that plays an essential role in DNA repair. … an androgen receptor–directed therapy, confirming clinical benefit for an indication that previously had accelerated approval.
Lenacapavir
go.drugbank.com/drugs/DB15673ApprovedInvestigational[L42995] On December 22, 2022, it was also approved by the FDA.[L44473] … HIV/AIDS remains an area of concern despite the introduction of numerous successful therapies, mainly due to the emergence of multidrug resistance and patient difficulty in adhering to treatment regimens
Synonyms: N-((1S)-1-(3-(4-CHLORO-3-(METHANESULFONAMIDO)-1-(2,2,2-TRIFLUOROETHYL)-1H-INDAZOL-7-YL)-6-(3-(METHANESULFONYL)-3-METHYLBUT-1-YN-1-YL)PYRIDIN-2-YL)-2-(3,5- DIFLUOROPHENYL)ETHYL)-2-((3BS,4AR)-5,5-DIFLUORO, 1H-CYCLOPROPA(3,4)CYCLOPENTA(1,2-C)PYRAZOLE, N-((1S)-1-(3-(4-CHLORO-3-((METHYLSULFONYL)AMINO)-1-(2,2,2-TRIFLUOROETHYL)-1H-INDAZOL-7-YL)-6-(3-METHYL-3-(METHYLSULFONYL)-1-BUTYN-1-YL)-2-PYRIDINYL)-2-(3,5-Strontium ranelate
go.drugbank.com/drugs/DB09267ApprovedWithdrawnAvailable for prescription use for a time in some parts of the world as Protelos (strontium ranelate) 2 g granules for oral suspension by Servier, it was ultimately discontinued in 2016-2017 owing to an … This agent presents an atypical mechanism of action in which it increases deposition of new bone by osteoblasts and, simultaneously, reduces the resorption of bone by osteoclasts.
Prednisolone acetate
go.drugbank.com/drugs/DB15566ApprovedInvestigationalVet approvedPrednisolone acetate is a [prednisolone] molecule bound to an acetate functional group by an ester bond.[L9449] Prednisolone acetate was granted FDA approval in 1955.[L9449]
Teriparatide
go.drugbank.com/drugs/DB06285ApprovedInvestigational[A251395] Teriparatide is used in the treatment of osteoporosis in men and women.[L42590, L42595] … [A251395] First approved in the United States in November 2002 and in Europe in April 2003,[A251400] teriparatide makes the first approved drug in a new category of osteoporosis therapy called anabolic
Products: SONDELBAY (Teriparatide) 20 micrograms/ 80 microliters solution for injection in pre-filled pen, Teriparatid ratiopharm 20 Mikrogramm/80 Mikroliter Injektionslösung in einem vorgefüllten InjektorTriclocarban
go.drugbank.com/drugs/DB11155ApprovedIt is a bacteriostatic compound that has been found in antibacterial soaps and other personal care products. … Triclocarban, with the chemical formula C13H9Cl3N2O [L2675] is an antibacterial agent that is particularly effective against Gram-positive bacteria such as *Staphylococcus aureus*.
Synonyms: N-(4-chlorophenyl)-N'-(3,4-dichlorophenyl)ureaPhenmetrazine
go.drugbank.com/drugs/DB00830ApprovedIllicitA sympathomimetic drug used primarily as an appetite depressant. Its actions and mechanisms are similar to dextroamphetamine.
Acetazolamide
go.drugbank.com/drugs/DB00819ApprovedInvestigationalVet approvedIt is sometimes useful also as an adjunct in the treatment of tonic-clonic, myoclonic, and atonic seizures, particularly in women whose seizures occur or are exacerbated at specific times in the menstrual … Its antiepileptic effect may be due to its inhibitory effect on brain carbonic anhydrase, which leads to an increased transneuronal chloride gradient, increased chloride current, and increased inhibition
Synonyms: N-[5-(aminosulfonyl)-1,3,4-thiadiazol-2-yl]acetamide, N-[5-(aminosulfonyl)-1,3,5-thiadiazol-2-yl]acetamideProbenecid
go.drugbank.com/drugs/DB01032ApprovedInvestigationalProbenecid has also been used to treat patients with renal impairment, and, because it reduces the renal tubular excretion of other drugs, has been used as an adjunct to antibacterial therapy.
Categories: Preparations With No Effect on Uric Acid Metabolism, Compounds used in a research, industrial, or household settingSynonyms: 4-(N,N-Dipropylsulfamoyl)benzoesäure, 4-(Di-n-propylsulfamoyl)benzoesäureCaplacizumab
go.drugbank.com/drugs/DB06081ApprovedInvestigationalCaplacizumab was developed by Ablynx, a Sanofi company and FDA approved on February 6, 2019,[L5302] and approved previously by the EU in October 2018 as a combination therapy with plasma exchange and immunosuppression … [A174634]In December 2025, the FDA expanded this indication to include pediatric patients aged 12 years and older with aTTP, in the same combination regimen.[L54958,L54963]